Human bioactive Sclerostin ELISA

Catalog number: BI-20472
Brand: Biomedica
Packing: 96 tests
Price: € 699.00
Expected delivery time: 7 days
Quantity:

Product specifications for - Human bioactive Sclerostin ELISA

Overview: 
Product group: Assays
Category: ELISA / EIA
Application note: ELISA
Species: Human
Reactivity note: human
Properties: 
Molecular weight: 22.5 kDa
Assay Sensitivity: 1.9 pmol/l (= 42.7 pg/ml)
Assay Specificity: Sclerostin, SOST
Assay Precision: intra-assay: 1%, inter-assay: 5%
Assay Sample Type: Serum, EDTA plasma, citrate plama, urine, cell culture supernatant
Assay Time: 2 h / 1 h / 30 min
Assay Detection Range: 10-320 pmol/l
Datasheet: Datasheet
  Research Use Only
UNSPSC: 41116133
Scientific information: 
Scientific info: Product Characteristics: The Biomedica human bioactive Sclerostin (SOST) Sandwich ELISA kit is a quick day test intended for the quantitative measurement of bioactive Sclerostin levels in human serum and plasma samples (EDTA and citrate). The bioactive SOST ELISA specifically recognizes the Sclerostin osteoclast interacting (functional) domain. Target information: Canonical Wnt-signalling plays an important role in the regulation of bone homeostasis by promoting the development of osteoblasts. Negative regulators of the Wnt pathway are important therapeutic targets for the treatment of diseases with enhanced bone resorption. One of these molecules is Sclerostin, a 22.5 kD secreted glycoprotein, which acts by binding to the Wnt-coreceptor LRP5 thus preventing the binding of Wnt molecules.
Gene ID: 50964
Swiss prot ID: Q9BQB4
Safety information: 
MSDS: MSDS
Additional information: 
Synonyms: BI-20472; Biomedica Gruppe
Neto R et al., “Low bone turnover is associated with plain X-ray vascular calcification in predialysis patients.” PLoS One. (2021); 13;16(10):e0258284. Read more
Maïmoun L et al., “Periostin and sclerostin levels in individuals with spinal cord injury and their relationship with bone mass, bone turnover, fracture and osteoporosis status.” Bone. (2019); 127:612-619 Read more
Wakolbinger R et al., “Serum levels of sclerostin reflect altered bone microarchitecture in patients with hepatic cirrhosis.” Wien Klin Wochenschr. (2020); 132(1-2):19-26. Read more
All Citations Read more